Dimitris Repantis
Dr. med.; Lead Psychedelic Substances Research Group
Data updated
Research Footprint
Dimitris Repantis appears in 7 tracked papers (2021–2026), most studied alongside Psilocybin, Placebo and 5-MeO-DMT, across Depressive Disorders, Treatment-Resistant Depression (TRD) and PTSD.
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: Guy Goodwin, Scott Tyler Aaronson and Robin Carhart-Harris.
Background & Research
Dimitris Repantis is a physician and psychiatrist at Charité – Universitätsmedizin Berlin. He leads the Psychedelic Substances Research Group and is involved in research on psychedelic-assisted treatments, including clinical, ethical, and safety-related questions. His recent work spans psilocybin studies in depression and broader psychedelic policy and ethics discussions.
Key Impact
A psychiatrist and researcher leading psychedelic-substances work at Charité, contributing to multiple prominent psilocybin and psychedelic safety/ethics studies.
Collaboration Network
33 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Dimitris Repantis's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Dimitris Repantis is associated with.